Rezenopy Spray
NDC 83245-003
Product Information
Rezenopy (naloxone hcl) is a NDA-approved product labeled by Scienture Llc. This medication is used to treat known or suspected opioid overdose. It is supplied as a spray for nasal administration. This product entry covers the primary NDC 83245-003 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 83245-003?
What are the uses of this product?
What are Active Ingredients of this product?
- NALOXONE HYDROCHLORIDE 10 mg/.11mL - A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- NALOXONE HYDROCHLORIDE (UNII: F850569PQR)
- NALOXONE (UNII: 36B82AMQ7N) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- GLYCERIN (UNII: PDC6A3C0OX)
- TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2704891 - naloxone hydrochloride 10 MG in 0.11 mL Nasal Spray
- RxCUI: 2704891 - naloxone hydrochloride 90.9 MG/ML Nasal Spray
- RxCUI: 2704891 - naloxone hydrochloride 10 MG (naloxone 9 MG) per 0.11 ML Nasal Spray
- RxCUI: 2704898 - REZENOPY 10 MG in 0.11 mL Nasal Spray
- RxCUI: 2704898 - naloxone hydrochloride 90.9 MG/ML Nasal Spray [Rezenopy]
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.